Kornimate/medical-research-clean huggingface dataset:
same-day discharge after coronary percutaneous transluminal coronary angioplasty (ptca)

Conditions: Acute Coronary Syndrome

Summary: same day discharge is safe and feasible in selected troponin negative patients undergoing coronary planned percutaneous coronary intervention (pci) or ad hoc pci via the transfemoral approach.

the feasibility and safety of same day discharge post pci will be examined. study data will be compared to national registries and national or regional databases of pci in troponin negative patients with overnight stay. as part of the registry we will also assess compliance with dual antiplatelet therapy at six months and at 1 year and will record any reasons for premature discontinuation as well as any associated adverse events.

Eligibility criteria:
inclusion criteria: 1. scheduled for catheterization/coronary angiography 2. undergoing diagnostic coronary angiography to define the coronary anatomy with the intent for revascularization (ad-hoc pci) or planned pci to define the coronary anatomy with the intent for revascularization due to one of the following: 1. exertional or rest chest pain (or angina equivalent) 2. abnormal exercise stress test 3. abnormal nuclear tests 4. abnormal pharmacologic or stress echocardiogram, or pharmacologic mri 5. abnormal ekgs 6. abnormal calcium scores 7. abnormal coronary ct angiogram 3. ability and willingness to consent and authorization for use of phi exclusion criteria: 1. acs (stemi, ua/nstemi) 2. positive troponin i per local laboratory standards 3. known ef\<30% 4. gfr\<50% (calculation using the idms-traceable mdrd study equation 5. dye allergy that unable to be safely premedicated 6. known current or history of bleeding diathesis 7. current or anticipated treatment with warfarin, oral factor xa inhibitor, oral direct thrombin inhibitor, lmwh, or tnk 8. known platelet count \ 1.5 at time of enrollment 9. hgb \<10 g/dl and/or hct \< 30% 10. residence \>60 minutes from the hospital 11. reliable caregiver not available for home post pci recovery 12. participation in another study that would require hospital procedures or test post pci prior to discharge 13. inability or unwillingness to consent for study, follow up procedures and authorization for use of phi 14. physician clinical determination participant is not suitable for study participation

Keywords: acute coronary syndrome percutaneous coronary angioplasty troponin negative cardiac
a research study looking at how a single dose of the medicine nnc0194-0499 behaves in chinese men

Conditions: Non-alcoholic Fatty Liver Disease

Summary: this study looks at how a new study medicine called nnc0194-0499 behaves in the body of chinese men. three different dose levels will be tested. participant will get only one of the three different dose levels of nnc0194-0499. which dose participant will get will be decided by chance. nnc0194-0499 is a medicine under clinical investigation. it means that the medicine has not yet been approved by the health authorities. participant will get 1 or 2 injections of the study medicine. it will be injected with a needle into a skin fold on stomach. the study will last for a maximum of 64 days. participant will not be able to take part in the study if the study doctor considers there is a risk for participant's health.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * chinese male aged 20-55 years (both inclusive) at the time of signing informed consent. * body mass index (bmi) between 23.0 and 34.9 kilograms per meter square (kg/m\^2) (both inclusive). * body weight greater than or equal to 60 kg. * considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: * known or suspected hypersensitivity to study intervention or related products. * any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
efficacy and safety evaluation of fecal microbiota transplantation in irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: participants will be given fmt through oral capsules or nasojejunal tube once a month. after three-time treatment, participants were followed up for three months. participants complete specific scales to assess improvement in symptoms, emotion and quality of life. besides, they report adverse effects and collect fecal samples at each visit.

this prospective, single-arm interventional study aims to evaluate efficacy and safety of fecal microbiota transplantation in refractory ibs patients. patients meeting the inclusion and exclusion criteria will provide written informed consent and receive fmt from healthy donors for three times. the administration methods include taking oral capsule or delivering microbiota suspension into the duodenum via nasojejunal tube. the patients receive treatment once a month and will be followed up for 3 months. improvement in ibs symptoms, emotion and quality of life were assessed through ibs symptom severity scale (ibs-sss), gastrointestinal symptom rating scale (gsrs), ibs-global assessment of improvement (ibs-gai), self-rating anxiety scale (sas), self-rating depression scale (sds) and ibs-quality of life (ibs-qol) respectively. patients were asked to complete these scales and collect fecal samples at baseline, post-fmt and at 1, 2, 3 and 4 months after fmt. primary endpoints were improvement in ibs-sss score and global symptoms after three-time fmt. secondary endpoints include change in gsrs score, improvement in emotion and quality of life at post-fmt, 1 and 6 months, as well as change in fecal microbiota composition.

Eligibility criteria:
inclusion criteria: * patients who fulfilled the rome iv criteria for the diagnosis of ibs, aged 18-70 years; * patients who have experienced failure of at least 3 conventional therapies for ibs; * absence of red flags such as weight loss, hematochezia; exclusion criteria: * pregnant, planning pregnancy or lactating; * psychiatric disorder or unable to cooperate with treatment and follow-up visit; * immunodeficiency or treatment with immune-modulating medication; * use of probiotics within the previous 3 months or treatment with antibiotics within 1 month prior to study entry; * having undergone any abdominal surgery, with the exception of appendectomy, cholecystectomy, caesarean section and hysterectomy; * presence of uncontrolled diabetes, hypertension, thyroid disease or other systemic disease; * presence of severe diseases related to heart, brain, kidney and lung or concomitant malignancies;
arthralgia of the temporomandibular joint. pain relief following one intra-articular injection of methylprednisolone

Conditions: Arthralgia; TMJ

Summary: the hypothesis is that a single dose intra-articular injection of corticosteroids are effective in relieving temporomandibular arthralgia pain. the purpose of the study is therefore to evaluate the effect of a single dose intra-articular methylprednisolone vs. placebo in a month perspective on subjects with unilateral arthralgia of the tmj.

this is a randomized blinded multicenter controlled study on 64 subjects (18 years or older) with the diagnosis of unilateral arthralgia of the tmj. the subject visit the clinic at three occasions; one enrollment visit, one baseline treatment visit and one evaluation visit one month after baseline. one week after baseline a follow-up telephone call is made with the purpose to track adverse events. pain questionaries are completed morning, lunch and dinnertime during three days before treatment, five days after treatment and three days proceeding the evaluation visit. the study ís planned to commence 10th december 2013 and last patient out 15th january 2015.

Eligibility criteria:
inclusion criteria: * age 18 or above * the diagnosis arthralgia in one tmj * understands swedish both verbally and in written * signed informed concent exclusion criteria: * tmj sounds in terms of clicking (crepitation allowed)) * polyarthritis/connective tissue disease * bilateral tmj arthralgia * fibromyalgia or other generalized pain * ongoing infection * ongoing dental treatment * intra-articular corticosteroid injection of a tmj the past 6 months * previous surgery of the affected tmj * complex psychiatric/psychologic status * institutionalized living including prisoners * staff at the investigational clinic * hypersensitive to local anesthetics * hypersensitive to methylprednisolone * hemophilia * methemoglobinemia * nursing * compromized health status according to the judgment of the investigator * concommitant use of the drugs cyclosporine, erythromycin, pentobarbital, itraconazole, ketoconazole, rifampicin, acetylsalicylic acid, oral anticoagulant * mentally retarded

Keywords: arthralgia temporomandibular joint corticosteroids injection intra-articular
probiotics in pediatric chronic cholestasis

Conditions: Cholestatic Liver Disease

Summary: double blinded rct (probiotics vs placebo) given to pediatric patients with chronic cholestasis for 4 weeks duration. baseline characteristics (antropometry, gastrointestinal symptoms, laboratory examinations) would be compared pre vs post treatment

in mice model of cirrhosis and ascites, there is an increased intestinal permeability (leaky gut syndrome), subsequently leads to bacterial translocation. bacterial translocation ultimately leads to bacterial overgrowth and increases associated morbidity, for instance, protracted diarrhea. this rct aims to administer probiotics product (lacto-b) in pediatric patients with chronic cholestasis (cholestasis \> 4 weeks, evidenced from laboratory examination results). method: double-blinded rct regimen: (identical, plain silver packaging, with code 0/1 --\> revealed by 3rd party upon study completion) intervention group: lacto-b 2 sachet per day for 4 weeks (28 days) each sachet of lacto-b contains: viable counts 1 x 107 cfu/g living bacteria in dual ph dependent release coated (lactobacillus acidophilus, bifidobacterium longum, streptococcus thermophilus), vitamin c 10 mg, vitamin b1 0.5 mg, vitamin b2 0.5 mg, vitamin b6 0.5 mg, niacin 2 mg. control group: placebo sachet (saccharum lactis 1gr) outcomes will be measured following completion of 4 weeks-course of probiotics/placebo

Eligibility criteria:
inclusion criteria: * diagnosed with chronic cholestasis (\>4 weeks evidence of cholestasis from laboratory evidence) * patient/guardian give consent to participate exclusion criteria: * immunocompromised * consumed antibiotic within 2 weeks prior to recruitment time * patient already consuming probiotic-added formula (any probiotic supplementation or formula milk with added probiotic)
time course and prognostic significance of pulmonary artery pressure in highlanders.

Conditions: High Altitude Pulmonary Hypertension; Sleep Apnea

Summary: the purpose of the current study is to evaluate the clinical and physiologic course of kyrgyz highlanders with high altitude pulmonary hypertension (haph) by performing a longitudinal cohort study. to this end, the investigators will invite the same highlanders who participated in the study in 2012 to undergo follow-up examinations in 2017, in order to allow comparisons of current results with baseline data from 2012.


Eligibility criteria:
inclusion criteria: * high altitude pulmonary hypertension confirmed by clinical presentation and mean pulmonary artery pressure \>30 mmhg measured by echocardiography at altitude of residence. * healthy subjects (high altitude controls) * both genders * age \>16 y * kyrgyz ethnicity * born, raised and currently living at \>2500 m * healthy subjects currently living at \<1000 m (low altitude controls) exclusion criteria: * pulmonary hypertension from other causes, in particular from left ventricular failure as judged clinically and by echocardiography * excessive erythrocytosis * other coexistent disorders that may interfere with the cardio-respiratory system and sleep * regular use of medication that affects control of breathing * heavy smoking

Keywords: high altitude illness pulmonary hypertension sleep apnea disease progression hypoxia
treatment of influenza in routine clinical practice

Conditions: Influenza; Acute Upper Respiratory Infection

Summary: this study evaluates the statistics of influenza and acute respiratory viral infections (arvi) management in outpatient sites in russia, armenia, moldova and georgia (epidemiology: disease severity and bacterial exacerbations; patients demography; treatment duration and timelines; safety; quality of treatment) in routine clinical practice with focus on drug therapy and usage of interferons' inducers.

this non-interventional study covers more than 15000 patients from outpatient sites in russia, armenia, moldova and georgia. influenza and acute respiratory viral infections (arvi) diagnosis validate according to "world health organization (who) guidelines for pharmacological management of pandemic influenza a (h1n1) 2009 and other influenza viruses". all patients' examinations are carried out according to the local routine clinical practice and local and international standards of care. the following data will be collected and analyzed after the end of treatment: * demography * disease severity * body temperature * chills and fever (no/mild/severe) * weakness (no/mild/severe) * muscle or joint pain (no/mild/severe) * rhinitis (yes/no) * throat irritation (no/mild/severe) * headache (no/mild/severe) * cough (no/mild/severe) * conjunctivitis (no/mild/severe) * timelines: disease onset, first visit to physician, start of treatment * therapy (drug name, dose, with focus on interferons' inducers) * bacterial exacerbations (yes/no) * therapy of bacterial exacerbations (drug name) * adverse events * results of treatment satisfaction questionnaire for medication (tsqm-9), if completed by patient

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old, * patients diagnosed with influenza or influenza-like illness caused by a different type of virus, * patients to whom anti-flu treatment administered, * patients who have signed informed consent for management of their personal data. exclusion criteria: * no exclusion criteria except participating in a current clinical trial because of non-interventional sudy design

Keywords: influenza flu acute respiratory viral infection arvi acute upper respiratory infection auri
hypersensitivity reaction to vitrase (ovine hyaluronidase)

Conditions: Drug Hypersensitivity

Summary: the objective of this study was to rule out a greater than 10% incidence of hypersensitivity to vitrase following a single intradermal injection of 3 usp units vitrase. less than or equal to 10% hypersensitivity response was considered acceptable.


Eligibility criteria:
inclusion criteria: * avoid disallowed meds throughout study exclusion criteria: * known hypersensitivity to hyaluronidase and/or bee sting * atopic individuals assessed by med history * topical/systemic corticosteroids within 30 days * concurrent use of antihistamines or anti-inflammatory during study * active or chronic disease likely to affect immune function * history of alcohol/drug abuse within 6 months
secondary prevention education after acute myocardial infarction

Conditions: Myocardial Infarction, Acute; Anxiety; Education; Quality of Life

Summary: the aim of this study is to examine the effect of secondary prevention education given to individuals after acute myocardial infarction on physiological parameters, anxiety and quality of life.

the aim of this study is to examine the effect of secondary prevention education given to individuals after acute myocardial infarction on physiological parameters, anxiety and quality of life.the population of the study will be the individuals hospitalized with the diagnosis of acute myocardial infarction in the coronary intensive care unit of abant izzet baysal university izzet baysal training and research hospital. the study will be conducted in a randomized controlled manner with two groups, 43 in the control group and 43 in the secondary prevention education group. cag (coronary angiography) procedure training form, patient identification form, physiological parameters form and visual analogue scale, spielberg state and trait anxiety scale and myocardial infarction dimensional assessment scale will be used to collect data. the data will be collected by face to face interview technique. for descriptive statistics, mean and standard deviation or median and minimum-maximum values for numerical variables, number and percentage values for categorical variables will be given. the kolmogorov-smirnov test (p \<0.05), skewness and kurtosis coefficients (should be ± 1) and x ̅ / ss \<4 inequalities will be examined at the same time, and the weight in which group will be preferred.

Eligibility criteria:
inclusion criteria: * first time ami and inpatient treatment in the coronary intensive care unit, * not having received training after ami \* * being 18 years or older, * speak turkish, * no problem in verbal communication, * absence of hearing loss, * not being diagnosed with a psychiatric illness, * being conscious, * being volunteer to participate in the study, * routine check of cholesterol, hdl, ldl, triglyceride results at the beginning of the study and at 6 months. exclusion criteria: not having had ami for the first time * having received training after ami * not willing to participate in the study, * cannot speak turkish, * problems in verbal communication, * having hearing loss, * having a diagnosis of psychiatric illness, * unconsciousness. * cholesterol, hdl, ldl, triglyceride results were not routinely checked at the start and 6 months of the study.

Keywords: myocardial infarction anxiety education quality of life
retrospective analysis of skin/soft tissue primary nk/t cell lymphoma

Conditions: Extranodal NK/T Cell Lymphoma

Summary: to study clinical features, prognostic factors and treatment outcome and to develop a possible prognostic index in skin/soft tissue primary nk/t cell lymphoma patients.


Eligibility criteria:
inclusion criteria: * histologically confirmed extranodal nk/t cell lymphoma * primary site is skin or soft tissue exclusion criteria: * involvement of upper aerodigestive tract
effectiveness of cryotherapy study for prostate cancer

Conditions: Prostate Cancer

Summary: this is a single-centre prospective, non-randomized trial to investigate the efficacy of cryotherapy in patients with localized prostate cancer.the aim of study is to investigate the safety profile of cryotherapy in the treatment of prostate cancer and to evaluate the oncological control of prostate cancer by means of cryotherapy focal treatment.

conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. however, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. active surveillance carries the risk of disease progression and psychological distress to the patients. focal therapy employs the concept of only destroying the significant lesion, resulting in disease cure and improved functional outcome. among the different options of focal therapy, cryotherapy is one of the most commonly employed energy sources. it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue. our study aims at assess the safety and effectiveness of such treatment in prostate cancer management

Eligibility criteria:
inclusion criteria: * men aged between 40 - 85 years * visible index lesion(s) on mri * found to have localized prostate cancer after mri-usg fusion targeted biopsy: 1. clinical tumour stage \<= t2, or 2. gleason score \<= 7, or 3. psa \<= 20 ng/ml exclusion criteria: * patients unfit for contrast mri exam * patients with active urinary tract infection * patients with bladder pathology including bladder stone and bladder cancer * patients with urethral stricture * patients with neurogenic bladder and/or sphincter abnormalities * patients who fail to give informed consent

Keywords: prostate cancer focal therapy cryotherapy
progressively decreasing titration schedules of bifeprunox in subjects with schizophrenia or bipolar disorder

Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder

Summary: this study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. study duration is 2 months with an optional open-label 26-week extension study.


Eligibility criteria:
inclusion criteria: * subjects with the current diagnosis of schizophrenia, bipolar type i disorder according to dsm-iv tr criteria * age 18 to 55 * body weight 100-250 lbs * be sufficiently stable to allow discontinuation of antipsychotic medication exclusion criteria: * acutely psychotic subjects * subjects that are acutely manic * subjects with a psych diagnosis other than bipolar type i disorder

Keywords: decreasing titration study schizophrenia bipolar pharmacokinetic
can quantitative mri after ctace help predict survival ?

Conditions: Hepatocellular Carcinoma (HCC)

Summary: transcatheter arterial chemoembolization (tace) is a widely accepted palliative therapy for the treatment of hcc. palliative means that it does not cure the disease prolongs your life and improves quality of life. during tace, a mixture of chemotherapy drugs is combined with an oil called lipiodol. lipiodol has a role as both drug carrier and embolic agent (a material that blocks blood flow to tumors). the lipiodol/chemotherapy mixture is injected into an artery (blood vessel) directly supplying blood to a hcc tumor. lipiodol is made up of fat and water which can be seen on mri. therefore, mri can be used to quantify the amount of lipiodol delivered to the hcc tumors. in this study, the investigators want to see if patient survival is related to the amount of lipiodol delivered to hcc tumors.


Eligibility criteria:
inclusion criteria: * prospective studies will be performed in 20 patients with hepatocellular carcinoma (hcc) independently scheduled to undergo tace; tumors in each of these candidates will already have been deemed un-resectable. * reasons may include * concurrent co-morbidities including cardiac or respiratory compromise * recurrent or multi-lobar disease * cirrhosis or portal hypertension * vascular invasion * high tumor burden * contraindications to general anesthesia. * diagnosis of hcc will have been established by a) biopsy or b) non-invasively, based upon \> 2cm diameter tumor with characteristic imaging findings in the setting of cirrhosis. * male or female aged 18 to 89 years, all ethnicities exclusion criteria: * infiltrative or diffuse hcc. * does not meet inclusion criteria. * pregnant women. * individuals with pacemakers or other non-mri compatible metallic implants. * hemodialysis patients or patients with severely impaired renal function. * individuals with severe claustrophobia or unwilling to get a mri.

Keywords: hepatocellular carcinoma hcc lipiodol